

**BEVERLY JCG LTD.**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 200505118M)

---

**PERIODIC ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES OF  
SINGAPORE EXCHANGE SECURITIES TRADING LIMITED**

---

The board of directors (the “**Board**” or “**Directors**”) of Beverly JCG Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”), would like to announce the share transactions that occurred during the three-month period from 1 July 2021 to 30 September 2021, pursuant to Rule 706A of the Catalist Rules of Singapore Exchange Securities Trading Limited.

*In this announcement, unless otherwise stated, the exchange rate applied by the Group for conversions of RM into S\$ is RM3: S\$1. The exchange rate is for reference only. No representation is made by the Company that any amounts in S\$ have been, could have been or could be converted at the above rate or at any other rates or at all.*

**1. SHARE TRANSACTIONS**

**1.1 Increase in the issued and paid-up share capital of Beverly Ipoh Sdn Bhd (“Beverly Ipoh”) on a *pro rata* basis**

On 8 July 2021, Beverly Ipoh had allotted 50,000 ordinary shares and increased its issued and paid-up share capital from 400,000 ordinary shares to 450,000 ordinary shares on a *pro rata* basis by way of:

- (a) cash contribution of RM35,000 (or equivalent to approximately S\$12,000) by JCG-Beverly Pte. Ltd. (“**JCG-Beverly**”); and
- (b) cash contribution of RM15,000 (or equivalent to approximately S\$5,000) by Chong Yee Leng (“**Dr Elaine**”).

As the increase in the share capital of Beverly Ipoh was on a *pro rata* basis, the shareholding structure of Beverly Ipoh and the 70% shareholding interest of JCG-Beverly in Beverly Ipoh remained the same. In connection with this, the details of the issue and allotment of shares pursuant to the increase in capital are as follows:

<b>Shareholders</b>	<b>Before allotment of shares</b>	<b>No of ordinary shares allotted</b>	<b>After allotment of shares</b>	<b>Shareholding percentage</b>
Howard Ng How Er (holding on trust for JCG-Beverly by way of a trust deed dated 17 April 2020 and the supplemental trusts deed dated 11 June 2021 and 8 July 2021)	280,000	35,000	315,000	70% <sup>(1)</sup>

Dr Elaine	120,000	15,000	135,000	30%
Total	400,000	50,000	450,000	100%

(1) While there is no direct shareholding, JCG-Beverly holds a deemed interest of 70% through the trust arrangement.

The above transaction by JCG-Beverly was funded through internal resources and is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 December 2021.

Based on the audited financial statements of Beverly Ipoh as at 31 December 2020, Beverly Ipoh is in a net liability position of RM122,000 (approximately S\$41,000).

The proceeds amounting to RM50,000 (approximately S\$17,000) were utilised for general working capital of Beverly Ipoh mainly in relation to administrative and operating expenses.

Please refer to the Company's announcement dated 8 July 2021 for additional information.

## 1.2 Increase in the issued and paid-up share capital of Beverly Dentistree Sdn Bhd ("**Beverly Dentistree**") on a non *pro rata* basis

On 8 July 2021, Beverly Dentistree had allotted 349,900 ordinary shares and increased its issued and paid-up share capital from 100 ordinary shares to 350,000 ordinary shares on a non *pro rata* basis by way of:

- (a) cash contribution of RM244,900 (or equivalent to approximately S\$82,000) by JCG-Beverly; and
- (b) cash contribution of RM105,000 (or equivalent to approximately S\$35,000) by Arlena Philip Lee ("**Dr Arlena**").

In connection with this, the details of the issue and allotment of shares pursuant to the increase in capital are as follows:

Shareholders	Before allotment of shares	No of ordinary shares allotted	After allotment of shares	Shareholding percentage after allotment of shares
JCG-Beverly	100	244,900	245,000 <sup>(1)</sup>	70%
Dr Arlena	-	105,000	105,000	30%
Total	100	349,900	350,000	100%

- (1) JCG-Beverly intends to enter into a trust agreement (the "**Trust Deed**") with Howard Ng How Er (the "**Trustee**"), a director of the Company, to hold 245,000 shares in Beverly Dentistree on trust for JCG-Beverly. The rationale for entering into the Trust Deed with the Trustee is to facilitate Beverly Dentistree's application for the private clinic license in Malaysia, which requires the shareholdings of Beverly Dentistree to be locally held (i.e. Malaysian-held) and not foreign-owned based on the

relevant laws and regulations of the Ministry of Health of Malaysia as at the date of this announcement. The Company will update shareholders in due course.

The above transaction was funded through internal resources and is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 December 2021.

Based on the audited financial statements of Beverly Dentistree as at 31 December 2020, Beverly Dentistree is in a net liability position of RM150,000 (approximately S\$50,000).

The proceeds amounting to RM349,900 (approximately S\$117,000) were utilized to settle the consideration amount of RM350,000 (approximately S\$117,000) for the acquisition of Klink Pergigian Dentistree's assets and equipment, the database of all clients and the operating business. Please refer to the Company's announcement on 5 May 2021 for further details of this acquisition.

Please refer to the Company's announcement dated 9 July 2021 for additional information.

### 1.3 Striking off of dormant subsidiaries

The Group's three wholly-owned dormant subsidiaries, China iMyth Company Pte. Ltd. ("**China iMyth**"), CMIC Hemodialysis Pte Ltd ("**CMIC Hemo**") and JCG Health Pte. Ltd. ("**JCG Health**") in Singapore, have been struck off from the register on 10 August 2021.

The net tangible assets of China iMyth, CMIC Hemo and JCG Health are S\$Nil, S\$Nil and S\$Nil respectively as at 31 December 2020. The strike off of China iMyth, CMIC Hemo and JCG Health is not expected to have any material impact on the consolidated net tangible assets and earnings per share of the Company and the Group for the financial year ending 31 December 2021.

Please refer to the Company's announcement dated 12 August 2021 for additional information.

## 2. **INTERESTS OF DIRECTORS AND CONTROLLING SHAREHOLDERS**

Save as disclosed above, none of the Directors or controlling Shareholders of the Company and their respective associates has any interests, direct or indirect, in the transaction, other than through their respective shareholding interests in the Company, if any.

## 3. **RESPONSIBILITY STATEMENT**

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries that to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the increase in share capital set out in paragraph 1 above, and the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading. Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

#### 4. CAUTION IN TRADING

Shareholders are advised to read this announcement and any further announcements by the Company carefully, and should consult their stock brokers, bank managers, solicitors or other professional advisors if they have any doubt about the actions they should take.

#### BY ORDER OF THE BOARD

Dato' Ng Tian Sang @ Ng Kek Chuan  
Executive Chairman and Chief Executive Officer

14 November 2021

---

*This announcement has been reviewed by the Company's sponsor, Stamford Corporate Services Pte. Ltd. (the "Sponsor").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Vanessa Ng (Telephone: +65 6389 3065 and Email: [vanessa.ng@morganlewis.com](mailto:vanessa.ng@morganlewis.com)).*